HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Malignant fibrous histiocytoma of skin — Clinical Guidelines

Overview

Malignant fibrous histiocytoma (MFH) of the skin is a rare, aggressive soft tissue sarcoma that primarily affects adults, often presenting as a firm, rapidly growing nodule with potential for local invasion and metastasis 6.

Diagnosis

Clinical presentation: Firm, rapidly enlarging skin nodule 6.

Biopsy confirmation: Histopathological examination essential for diagnosis, typically showing pleomorphic morphology with atypical giant cells 6.

Imaging: MRI or CT scans may be used to assess extent of local invasion and rule out metastasis 6.

Management

Surgical excision: Wide local excision with clear margins is the primary treatment 6.

Adjuvant therapy: Consideration of adjuvant radiotherapy for high-risk features such as deep invasion or incomplete excision 6.

Systemic therapy: Chemotherapy may be considered in advanced or metastatic disease, though evidence is limited 6.

Special Populations

Pregnancy: No specific guidelines provided in the abstracts [].

Pediatrics: Rare occurrence; management similar to adults but with caution due to growth considerations 6.

Elderly: Treatment approach similar to other adults, with emphasis on functional outcomes and comorbidities 6.

Comorbidities: Management should consider impact on overall health and treatment tolerance 6.

Key Recommendations

Surgical excision with clear margins is crucial for local control 6 (Evidence: Strong).

Consider adjuvant radiotherapy for high-risk features to reduce recurrence risk 6 (Evidence: Moderate).

Evaluate systemic therapy in advanced cases, though evidence is limited and should be individualized 6 (Evidence: Weak).

References

1 Sturges CI, Jain S, Velasquez M, Gedamu H, Komarovsky J, McDonald J et al.. Cutaneous Hormone Sampling and Analysis for Dermatologic Research. The Journal of investigative dermatology 2025. link 2 Bukvić Mokos Z, Tomić Krsnik L, Harak K, Marojević Tomić D, Tešanović Perković D, Vukojević M. Vitamin D in the Prevention and Treatment of Inflammatory Skin Diseases. International journal of molecular sciences 2025. link 3 Li Y, Cao Z, Wu J. Identifying novel risk targets in inflammatory skin diseases by comprehensive proteome-wide Mendelian randomization study. Postgraduate medical journal 2025. link 4 Watanabe C. Skin Improvement in Japanese Patients With Inflammatory Dermatologic Conditions Using the Injectable Hyaluronic Acid VYC-12. Journal of cosmetic dermatology 2025. link 5 Roster K, Xie L, Nguyen T, Lipner SR. Impact of Ketogenic and Low-Glycemic Diets on Inflammatory Skin Conditions. Cutis 2024. link 6 Cai Y, Zhu Y, Wang Y, Xiang W. Intense pulsed light treatment for inflammatory skin diseases: a review. Lasers in medical science 2022. link 7 Lynde C. Moisturizers for the treatment of inflammatory skin conditions. Journal of drugs in dermatology : JDD 2008. link

Malignant fibrous histiocytoma of skin